Tillotts Pharma launches new dosage strength of Octasa in Canada
Tillotts, part of the Japanese Zeria Group, is offering Octasa 1600 mg (mesalazine) delayed-release tablets as first-line treatment for moderately active ulcerative colitis in Canada.
“Tillotts has a longstanding history of more than 40 years in delivering mesalazine formulations for the treatments of patients suffering from UC, and I am very excited about the opportunity to strengthen our commercial presence in Canada by launching Octasa 1600 mg tablet as a new high strength mesalazine tablet treatment option," said Adrian Hill, global head of commercial operations at Tillotts. "This has been achieved through the solid strategic partnership between Tillotts and Pendopharm.”
[Read more: AllianceRx Walgreens Prime, Walgreens study adherence in cystic fibrosis, ulcerative colitis/crohn’s disease patients]
"Earlier this year, we announced the launch of Octasa 800 mg, and we are delighted to continue our strong relationship with Tillotts by bringing Octasa 1600 mg to Canadian patients suffering from moderately active ulcerative colitis," said Jad Isber, vice president and general manager at Pendopharm. "The addition of Octasa 1600 mg to our portfolio will further enhance Pendopharm’s leadership position in gastroenterology, bringing a new treatment option to healthcare professionals and patients."